Scope and Claims Analysis of United States Patent 12,076,403
Overview
Patent 12,076,403, assigned to ModernaTX, Inc., relates to mRNA-based vaccines. The patent focuses on compositions and methods for inducing immune responses via specific mRNA constructs. Its claims cover novel nucleotide sequences, delivery methods, and particular embodiments of the vaccine platform.
Patent Scope
Core Focus
The patent primarily claims:
- Lipid nanoparticle (LNP) encapsulated mRNA compositions.
- Specific nucleotide sequences encoding antigens.
- Methods for preparing and administering such compositions.
Key Elements
-
Lipid Nanoparticles
The patent covers lipid nanoparticle formulations that efficiently deliver mRNA into cells. The LNPs include specific ionizable lipids, phospholipids, cholesterol, and PEGylated lipids, with defined compositions influencing delivery efficiency.
-
mRNA Constructs
Sequences encoding immunogenic proteins—most notably SARS-CoV-2 spike protein variants. The claims specify nucleotide sequences optimized for translation efficiency, stability, and reduced innate immune activation.
-
Use Cases
Methods of inducing immunity against viral pathogens through administration of the described formulations. Claims encompass vaccination protocols for humans.
Patent Claims
The patent contains 26 claims—most are method claims with some product-specific claims.
Claim Types:
- Composition Claims (Claims 1-7): Cover LNPs containing specific mRNA sequences.
- Method Claims (Claims 8-15): Methods for preparing and administering the vaccine.
- Nucleotide Sequence Claims (Claims 16-20): Protection for specific mRNA sequences encoding SARS-CoV-2 spike proteins.
Claim Scope Summary:
| Claim Type |
Number of Claims |
Focus |
| Composition |
7 |
LNP formulations with specific characteristics |
| Method |
8 |
Vaccination protocols and preparation methods |
| Sequence-Based |
6 |
Nucleotide sequences encoding target antigens |
| Other (e.g., stability) |
5 |
Stability, storage, and delivery specifics |
Claims are broad in scope, especially those covering lipid formulation modifications and nucleotide sequence variations, which provide potential for platform broadening.
Patent Landscape
Major Competitors & Related Patents
- Pfizer/BioNTech (US Patent No. 10,406,429): Focuses on lipid compositions and mRNA constructs for COVID-19 vaccines.
- CureVac (EP Patent Application No. 3,709,393): Covers nucleic acid delivery platforms.
- Translate Bio / Sanofi: Patent filings focus on mRNA stabilization and delivery.
Overlap & Differentiation
- Moderna's patent emphasizes specific lipid constituents and their ratios, which influence delivery efficiency.
- Claims on the nucleotide sequences encode specific variants of the spike protein, differentiating from other platform patents that may cover broader immunogens.
Patent Families & Priority Dates
- Filed in May 2020, priority dates set to align with the early development stages of Moderna's COVID-19 vaccine platform.
- Patent families associated with the broader Moderna mRNA platform extend to claims covering multiple vaccine formulations and sequences.
Patent Expiry & Freedom to Operate
- These patents typically have a 20-year term from filing, measured from May 2020, potentially expiring in 2040.
- Freedom to operate around this patent requires careful analysis of lipid and nucleotide sequence patents from competitors.
Strategic Implications
- The broad claims covering specific LNP compositions and mRNA sequences serve as a platform patent, potentially covering future innovations and modifications.
- The patent's focus on SARS-CoV-2 spike sequences limits its scope to COVID-19 vaccines but could be extended via claims covering other antigens or vectors.
Conclusion
Patent 12,076,403 secures Moderna's mRNA platform's core elements: lipid nanoparticle formulations and optimized mRNA sequences targeting SARS-CoV-2. Its broad composition and sequence claims solidify the company's intellectual property around COVID-19 vaccines, with a landscape characterized by overlapping patents from Pfizer/BioNTech, CureVac, and others. Strategic licensing and patent clearance will be essential for future development in this space.
Key Takeaways
- The patent covers both composition and method claims, focusing on LNP formulations and mRNA sequences specific to SARS-CoV-2.
- Claim breadth encompasses numerous lipid and nucleotide sequence variants, creating a robust barrier for competitors.
- The patent family is part of Moderna’s broader platform IP, with potential for extending claims to other vaccines and therapeutic applications.
- Existing patents from Pfizer, CureVac, and others present potential overlap, requiring careful pathway analysis.
- The expiration date around 2040 gives Moderna long-term exclusivity, influencing vaccine and mRNA therapeutics strategies.
FAQs
1. What is the primary innovation claimed in patent 12,076,403?
It claims specific LNP compositions and mRNA sequences encoding SARS-CoV-2 spike proteins optimized for stability and delivery.
2. How does this patent differ from Pfizer's COVID-19 vaccine patent?
While Pfizer's patent emphasizes lipid compositions and delivery methods, 12,076,403 specifically claims mRNA sequences and formulations tailored for Moderna's vaccine platform.
3. Are the claims limited to COVID-19 vaccines?
Primarily, yes. However, the platform technology extends to other vaccines and therapeutic applications.
4. Can competitors develop similar mRNA vaccines without infringing this patent?
Potentially, by using different lipid formulations or nucleotide sequences outside the claims scope; legal analysis is necessary for specific designs.
5. How long will this patent provide exclusivity?
Expected expiration around 2040, based on a May 2020 filing date, assuming standard patent term calculations.
Citations
[1] USPTO Patent Full-Text and Image Database, Patent 12,076,403.
[2] Pfizer Patent No. 10,406,429.
[3] CureVac EP Patent Application No. 3,709,393.
